Efficacy of PD-1 blockade in cervical cancer is related to a CD8+FoxP3+CD25+ T-cell subset with operational effector functions despite high immune checkpoint levels

Autor: A. M. Heeren, J. Rotman, A. G. M. Stam, N. Pocorni, A. A. Gassama, S. Samuels, M. C. G. Bleeker, C. H. Mom, H. J. M. A. A. Zijlmans, G. G. Kenter, E. S. Jordanova, T. D. de Gruijl

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-14 (2019)

Abstract Background Cervical cancer (CxCa) is mainly a locally invading disease that metastasizes to loco-regional lymph node basins before involving distant organs in more advanced stages. Local immune potentiation of tumor-draining lymph nodes (TDL

Externí odkaz: https://doaj.org/article/fd94363d85aa4764bcae05c3da897418

Long-term morbidity and health after early menopause due to oophorectomy in women at increased risk of ovarian cancer: Protocol for a nationwide cross-sectional study with prospective follow-up (HARMOny Study)

Autor: Marijke R. Wevers, M. Carola Zillikens, C. H. Mom, Eveline M. A. Bleiker, Klaartje van Engelen, Tim Leiner, Helena C. van Doorn, Lizet E. van der Kolk, Matti A. Rookus, Christi J. van Asperen, Margreet G. E. M. Ausems, Jeanine E. Roeters van Lennep, Sanne B. Schagen, Eleonora B.L. van Dorst, Marc van Beurden, Michael Hauptmann, Joanne A. de Hullu, Neil K. Aaronson, Maartje J. Hooning, Brigitte F. M. Slangen, Bernadette A. M. Heemskerk-Gerritsen, Marian J.E. Mourits, Katja N. Gaarenstroom, Encarna B. Gomez-Garcia, Irma van de Beek, Flora E. van Leeuwen, Margriet Collée, Lieke P.V. Berger, Lara Terra, Angela H.E.M. Maas

Publikováno v: JMIR research protocols, 10(1):e24414. JMIR Publications Inc.
JMIR Research Protocols
JMIR Research Protocols, 10(1). JMIR PUBLICATIONS, INC
Terra, L, Hooning, M J, Heemskerk-Gerritsen, B A M, van Beurden, M, Roeters van Lennep, J E, van Doorn, H C, de Hullu, J A, Mom, C, van Dorst, E B L, Mourits, M J E, Slangen, B F M, Gaarenstroom, K N, Carola Zillikens, M, Leiner, T, van der Kolk, L, Collee, M, Wevers, M, Ausems, M G E M, van Engelen, K, Berger, L P V, van Asperen, C J, Gomez-Garcia, E B, van de Beek, I, Rookus, M A, Hauptmann, M, Bleiker, E M, Schagen, S B, Aaronson, N K, Maas, A H E M & van Leeuwen, F E 2021, ' Long-Term Morbidity and Health After Early Menopause Due to Oophorectomy in Women at Increased Risk of Ovarian Cancer : Protocol for a Nationwide Cross-Sectional Study With Prospective Follow-Up (HARMOny Study) ', JMIR Research Protocols, vol. 10, no. 1, e24414, pp. e24414 . https://doi.org/10.2196/24414, https://doi.org/10.2196/24414
JMIR Research Protocols, 10
JMIR Research Protocols, 10, 1
JMIR Research Protocols, 10(1):e24414. JMIR Publications Inc.
JMIR Research Protocols, Vol 10, Iss 1, p e24414 (2021)
JMIR research protocols, 10(1):24414. JMIR PUBLICATIONS, INC

Background BRCA1/2 mutation carriers are recommended to undergo risk-reducing salpingo-oophorectomy (RRSO) at 35 to 45 years of age. RRSO substantially decreases ovarian cancer risk, but at the cost of immediate menopause. Knowledge about the potenti

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b3c6b7214e275ea3a8ac10324fbaf147
https://pure.amc.nl/en/publications/longterm-morbidity-and-health-after-early-menopause-due-to-oophorectomy-in-women-at-increased-risk-of-ovarian-cancer-protocol-for-a-nationwide-crosssectional-study-with-prospective-followup-harmony-study(a8d28a41-059f-48de-a1c2-ec5747a526e0).html

Less-favourable prognosis for low-risk endometrial cancer patients with a discordant pre- versus post-operative risk stratification

Autor: M.A. van der Aa, J.M.A. Pijnenborg, Hans W. Nijman, C. H. Mom, Harry Hollema, J.H. Becker, Gérard L. Bremer, W.J. van Driel, Carien L. Creutzberg, Florine A. Eggink, Anna K.L. Reyners, Roy F.P.M. Kruitwagen, Nicole P. M. Ezendam, K. Bouwman, A G van der Zee, G.C. Niemeijer, D. Boll

Publikováno v: European Journal of Cancer, 78, pp. 82-90
Eggink, F A, Mom, C H, Bouwman, K, Boll, D, Becker, J H, Creutzberg, C L, Niemeijer, G C, van Driel, W J, Reyners, A K, van der Zee, A G, Bremer, G L, Ezendam, N P, Kruitwagen, R F, Pijnenborg, J M, Hollema, H, Nijman, H W & van der Aa, M A 2017, ' Less-favourable prognosis for low-risk endometrial cancer patients with a discordant pre-versus post-operative risk stratification ', European Journal of Cancer, vol. 78, pp. 82-90 . https://doi.org/10.1016/j.ejca.2017.03.010
European Journal of Cancer, 78, 82-90. ELSEVIER SCI LTD
European Journal of Cancer, 78, 82-90. Pergamon
European Journal of Cancer: Official journal for European Organization for Research and Treatment of Cancer (EORTC), 78, 82-90. ELSEVIER SCI LTD
European Journal of Cancer, 78, 82-90

Contains fulltext : 174766.pdf (Publisher’s version ) (Closed access) BACKGROUND: Pre-operative risk stratification based on endometrial sampling determines the extent of surgery for endometrial cancer (EC). We investigated the concordance of pre-

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5fd6c1f6e680d7515afb47b80a594011
https://hdl.handle.net/2066/174766

Mapatumumab, a Fully Human Agonistic Monoclonal Antibody That Targets TRAIL-R1, in Combination with Gemcitabine and Cisplatin

Autor: N. L. Fox, Elisabeth G.E. de Vries, Jaap Verweij, Renée Miceli, Corina N.A.M. Oldenhuis, Walter J. Loos, C. H. Mom, Ferry A.L.M. Eskens, Jourik A. Gietema, Stefan Sleijfer

Publikováno v: Clinical Cancer Research, 15(17), 5584-5590. AMER ASSOC CANCER RESEARCH
Mom, C H, Verweij, J, Oldenhuis, C N A M, Gietema, J A, Fox, N L, Miceli, R, Eskens, F A L M, Loos, W J, De Vries, E G E & Sleijfer, S 2009, ' Mapatumumab, a fully human agonistic monoclonal antibody that targets TRAIL-R1, in combination with gemcitabine and cisplatin : A phase I study ', Clinical Cancer Research, vol. 15, no. 17, pp. 5584-5590 . https://doi.org/10.1158/1078-0432.CCR-09-0996
Clinical Cancer Research, 15(17), 5584-5590. American Association for Cancer Research Inc.

Purpose: To evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of mapatumumab, a fully human monoclonal antibody targeting tumor necrosis factor–related apoptosis–inducing ligand receptor 1 (TRAIL-R1), in combination with

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0207d91edcf7a5268f917729eed3d43c
https://doi.org/10.1158/1078-0432.ccr-09-0996

Venlafaxine versus clonidine for the treatment of hot flashes in breast cancer patients

Autor: J. Marina Maurer, Peter Nieboer, C. H. Mom, Elisabeth G.E. de Vries, A. N.Mac Hteld Wymenga, H. Marike Boezen, Robert S. De Jong, Pax H.B. Willemse, Marian J.E. Mourits, Ciska Buijs

Publikováno v: Breast Cancer Research and Treatment, 115(3), 573-580. Springer New York
Buijs, C, Mom, C H, Willemse, P H B, Marike Boezen, H, Maurer, J M, Wymenga, A N M H, De Jong, R S, Nieboer, P, De Vries, E G E & Mourits, M J E 2009, ' Venlafaxine versus clonidine for the treatment of hot flashes in breast cancer patients : A double-blind, randomized cross-over study ', Breast Cancer Research and Treatment, vol. 115, no. 3, pp. 573-580 . https://doi.org/10.1007/s10549-008-0138-7
Breast Cancer Research and Treatment, 115(3), 573-580. SPRINGER

Purpose Breast cancer patients with treatment-induced menopause experience frequent and severe hot flashes (HF). We compared venlafaxine and clonidine for the treatment of HF with regard to side effects, efficacy, quality of life and sexual functioni

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0ed8f11b2e31684b6af30250751a271e
https://doi.org/10.1007/s10549-008-0138-7